S&P 500
7,455.20
+0.03%
Dow Jones
52,276.10
-0.04%
Nasdaq 100
29,831.60
+0.11%
Russell 2000
3,009.07
-0.01%
FTSE 100
10,540.20
+0.33%
Nikkei 225
70,592.30
-0.09%
Jazz Pharmaceuticals

Jazz Pharmaceuticals (JAZZ) Q2 2025 Earnings

Reported Aug 5, 2025 at 4:08 PM ET · SEC Source

Q2 25 EPS

$-8.25

MISS 32.07%

Est. $-6.25

Q2 25 Revenue

$1.05B

MISS 0.14%

Est. $1.05B

vs S&P Since Q2 25

+105.1%

BEATING MARKET

JAZZ +122.2% vs S&P +17.1%

Market Reaction

Did JAZZ Beat Earnings? Q2 2025 Results

Jazz Pharmaceuticals delivered a bruising second quarter, posting an adjusted loss of $8.25 per share that missed the $6.25 consensus estimate by 32.07%, while revenue of $1.05 billion edged fractionally below expectations despite growing 2.1% year o… Read more Jazz Pharmaceuticals delivered a bruising second quarter, posting an adjusted loss of $8.25 per share that missed the $6.25 consensus estimate by 32.07%, while revenue of $1.05 billion edged fractionally below expectations despite growing 2.1% year over year. The quarter's defining event was a $905.36 million acquired in-process research and development charge tied to the Chimerix acquisition completed in April, which added dordaviprone to Jazz's oncology pipeline and drove the headline loss far beyond what analysts had modeled. Xywav remained the portfolio's clearest bright spot, generating $415.32 million in net product sales, up 13% year over year, while Epidiolex contributed $251.73 million; oncology softened to $274.15 million as Rylaze and Zepzelca each faced competitive headwinds. Looking ahead, Jazz narrowed its full-year revenue guidance to $4.15 billion to $4.30 billion while raising the floor of its non-GAAP adjusted EPS range, with near-term catalysts including a PDUFA date for dordaviprone on August 18 and Zepzelca's Priority Review decision due October 7.

Key Takeaways

  • • Xywav net product sales grew 13% YoY with approximately 625 net patient adds in Q2
  • • Total neuroscience revenue of $761.2 million, up 3% YoY
  • • Non-GAAP adjusted gross margin of 92.3%
  • • R&D expenses decreased YoY due to lower clinical study costs for zanidatamab and JZP385 discontinuation
24/7 Wall St

JAZZ YoY Financials

Q2 2025 vs Q2 2024, source: SEC Filings

24/7 Wall St

JAZZ Revenue by Segment

With YoY comparisons, source: SEC Filings

Q2 25 Q1 26

“It has been a privilege to lead Jazz over my 22-year tenure. I am proud of what we have achieved on behalf of patients and confident that our new President and CEO, Renee Gala, will build on Jazz's momentum and serve as a catalyst in driving long-term growth.”

— Bruce Cozadd, Q2 2025 Earnings Press Release

Back to JAZZ Stock Page